Introduction
Angiogenesis is a hallmark of cancer (1) . The VEGF signaling pathway is a key component of pathological angiogenesis in most cancers (2) (3) (4) (5) . To date, 10 anti-VEGF drugs have been approved by the FDA to treat various solid tumors, starting with metastatic colorectal cancer (CRC) in 2004 (1) . However, the survival benefit from these drugs is modest, as tumors develop resistance to these agents (3, 4, (6) (7) (8) (9) (10) (11) (12) (13) . The mechanisms of resistance remain far from understood.
The immune microenvironment has drawn great interest for its strong influence on tumor growth (7, 8, 10, 12, (14) (15) (16) (17) (18) (19) (20) (21) (22) . Emerging data show that the immune system also plays a critical role in refractoriness to antiangiogenic therapy (13, 23, 24) . Among various types of leukocytes, a growing body of evidence suggests that immunosuppressive innate immune cells contribute to this resistance in addition to cancer cell immune evasion (6, (25) (26) (27) . However, these myeloid cells are a collection of diverse subsets of CD11b + monocytic and granulocytic cells (27) (28) (29) (30) , which have often been studied together rather than as clearly defined subpopulations. Furthermore, Ly6C lo monocytes, also known as nonclassical monocytes, have not yet been clearly characterized or extensively investigated in the context of anti-VEGF cancer therapy. Particularly, it is not known whether Ly6C lo monocytes are capable of promoting immunosuppression in any context.
Moreover, mechanistic studies on the role of chemokines/ chemokine receptors in each specific subpopulation of innate immune cells in cancers have not been conducted, even though the importance of chemokines in leukocyte trafficking has long been widely accepted (31, 32) . The lack of suitable methods for in vivo longitudinal cellular-level monitoring of leukocytes in CRCs of small animal models has limited previous efforts to elucidate the highly dynamic immune microenvironment. Thus, the role and kinetics of specific subsets of innate immune cells in conferring resistance to anti-VEGF therapy are not known.
Here, we uncover a function of Ly6C lo monocytes -immunosuppression -and reveal that they instigate a cascade of immunomodulatory events in response to anti-VEGF therapy. We found that anti-VEGF therapy upregulates CX3CL1 expression, which facilitates CX3CR1-dependent infiltration of Ly6C lo monocytes.
Current anti-VEGF therapies for colorectal cancer (CRC) provide limited survival benefit, as tumors rapidly develop resistance to these agents. Here, we have uncovered an immunosuppressive role for nonclassical Ly6C lo monocytes that mediates resistance to anti-VEGFR2 treatment. We found that the chemokine CX3CL1 was upregulated in both human and murine tumors following VEGF signaling blockade, resulting in recruitment of CX3CR1 + Ly6C lo monocytes into the tumor. We also found that treatment with VEGFA reduced expression of CX3CL1 in endothelial cells in vitro. Intravital microscopy revealed that CX3CR1 is critical for Ly6C lo monocyte transmigration across the endothelium in murine CRC tumors. Moreover, Ly6C lo monocytes recruit Ly6G + neutrophils via CXCL5 and produce IL-10, which inhibits adaptive immunity. Preventing Ly6C lo monocyte or Ly6G + neutrophil infiltration into tumors enhanced inhibition of tumor growth with anti-VEGFR2 therapy. Furthermore, a gene therapy using a nanoparticle formulated with an siRNA against CX3CL1 reduced Ly6C lo monocyte recruitment and improved outcome of anti-VEGFR2 therapy in mouse CRCs. Our study unveils an immunosuppressive function of Ly6C lo monocytes that, to our knowledge, has yet to be reported in any context. We also reveal molecular mechanisms underlying antiangiogenic treatment resistance, suggesting potential immunomodulatory strategies to enhance the long-term clinical outcome of anti-VEGF therapies. 
Gr1
+ myeloid cells in our CRC models after DC101 treatment (Supplemental Figure 2A) . However, the CD11b +
+ cells represent a heterogeneous mixture of monocytic and granulocytic myeloid cells (28) (29) (30) 35 
Results

Anti-VEGFR2 therapy induces accumulation of monocytes and neutrophils in CRCs.
To examine the role of the immune microenvironment in CRCs, we utilized 2 syngeneic murine CRC models -SL4 and CT26 -orthotopically implanted in C57BL/6 and BALB/c mice, respectively. We also studied spontaneous rectal tumors in conditional Apc mutant mice (Apc fl/fl Ad-Cre) (33) . We used DC101, a monoclonal antibody against VEGFR2, to inhibit angiogenesis (34) . We observed vessel regression and increased hypoxia on days 5 and 12 after DC101 treatment compared with cant increase in neutrophils (510 ± 100 cells/mg in control vs. 1050 ± 190 cells/mg in DC101) ( Figure 1E ). Ly6C hi monocytes remained at similar levels between treatment groups on day 12 ( Figure 1E ). Given that the average size of the control group tumors harvested on day 5 and that of the DC101 group on day 12 were similar, the difference in the number of recruited Ly6C lo monocytes between 2 treatment groups is attributed to the treatment (IgG vs. DC101), not to the stage of tumor progression. In CT26 tumors, DC101 treatment showed similar kinetic response of Ly6C lo monocytes and neutrophils (Figure 1, F and G) . In spontaneous rectal tumors in conditional Apc mutant mice, we also observed Ly6C lo monocytes infiltrating prior to neutrophils (Supplemental Figure 3) . Figure 1C ), which have not been reported in tumors after anti-VEGF therapy. These cells display a high level of CX3CR1, while Ly6C hi monocytes and Ly6G + neutrophils (hereafter referred to as neutrophils) express CCR2 and CXCR2, respectively (25, 39, 44 ) (Supplemental Figure 2B) .
Anti-VEGFR2 therapy facilitates early infiltration of Ly6C lo monocytes into tumors. Among the 3 myeloid cell subpopulations found in SL4 tumors 5 days after DC101 treatment, there was a selective increase in Ly6C lo monocytes (380 ± 50 cells/mg) compared with the IgG control (180 ± 40 cells/mg), while the other 2 myeloid cell subsets did not change significantly ( Figure 1D ). On day 12, we observed a further increase in Ly6C lo monocytes (300 ± 70 cells/ mg in control vs. 700 ± 110 cells/mg in DC101) and also a signifi- lo monocytes were isolated from C57BL/6 WT or Cx3cr1 -/-mice (KO), fluorescently labeled, and adoptively transferred into DC101-treated SL4 tumor-bearing C57BL/6 WT animals. n = 7/group. Data are represented as mean ± SEM. *P < 0.05, 2-tailed t tests. Data are representative of 3 independent experiments (F and G). Scale bars: 100 μm (B-E). (31, 53) , it has now become questionable whether CX3CR1 is important for the process of Ly6C lo monocyte recruitment or not (50) . There have also been reports suggesting that CX3CR1 deficiency influences the survival of monocytes (54, 55) . To determine whether CX3CR1 is critical for Ly6C lo monocyte transmigration across the endothelium, we isolated Ly6C lo monocytes from both WT and Cx3cr1 -/-mice that were fluorescently labeled and adoptively transferred into DC101-treated WT mice bearing CRC tumors (Supplemental Videos 2 and 3). Measured by intravital microscopy, there was a significant decrease in the number of crawling Ly6C lo monocytes isolated from Cx3cr1 -/-mice compared with those isolated from WT mice ( Figure 2G ). These observations suggest that CX3CR1 plays an important role in chemotaxis-driven transmigration of Ly6C lo monocytes, especially in the process of rolling-crawling transition.
Blockade of VEGF/VEGFR2 signaling upregulates CX3CL1 in both human and mouse CRCs. Next, we examined which factors contribute to the CX3CR1-dependent attraction of Ly6C lo monocytes after DC101 treatment. CX3CL1, also known as fractalkine, is the only known ligand for CX3CR1 (31, 53) . Immunohistochemistry showed that CX3CL1 is dramatically upregulated after DC101 treatment ( Figure 3 ). Furthermore, biopsies of rectal carcinomas from patients before and after bevacizumab treatment (56, 57) also showed a significant increase in CX3CL1 expression after bevacizumab treatment ( Figure 3 , A-C).
By measuring protein levels, we found an increase in CX3CL1 in tumor tissues from day 2 onwards after DC101 treatment ( Figure 2E ). We found that DC101 significantly increased the number of rolling and crawling EGFP + Ly6C lo monocytes compared with the control on day 6 ( Figure 2F ). There was no significant change in the leukocyte-endothelial cell interaction in the control tumors over time ( Figure 2F ). These results show that the blood serves as the source of tumor-infiltrated Ly6C lo monocytes, rather than local proliferation of Ly6C lo monocytes in the tumor parenchyma, that interact with the tumor vessels and subsequently transmigrate across the endothelium in a time-dependent manner during antiangiogenic treatment. -/-mice showed not only a lack of Ly6C lo monocytes, but also significantly reduced infiltration of neutrophils compared with WT animals ( Figure 4E ). On the other hand, administration of an anti-Ly6G antibody selectively depleted Ly6G + neutrophils without affecting Ly6C lo monocytes ( Figure 4G and Supplemental Figure 3B ). These data indicate that early infiltration of Ly6C lo monocytes during anti-VEGFR2 treatment promotes subsequent recruitment of neutrophils to tumors.
Ly6C lo monocytes attract neutrophils via CXCL5 during anti-VEGFR2 treatment in CRCs. We then investigated the underlying mechanisms of how Ly6C lo monocytes attract neutrophils. Ly6C lo monocytes grown in vitro significantly increased the number of neutrophils that migrated to the bottom part of a Boyden chamber, while Ly6C hi monocytes did not ( Figure 4H ). DC101-treated tumors, characterized by abundant infiltration showed reduced expression of CX3CL1 ( Figure 3F ). The reduction in CX3CL1 levels was recovered by using DC101 to block VEGF/VEGFR2 signaling ( Figure 3F ). These results suggest that CX3CL1 is produced by endothelial cells and that production is regulated by VEGFR2 signaling. Furthermore, since the elevation of CX3CL1 expression precedes the induction of hypoxia ( Figure  3E and Supplemental Figure 1D ), this process may not be hypoxia dependent, although we cannot rule out the contribution of hypoxia in the later time points. Thus, blockade of VEGF/VEGFR2 signaling stimulates robust upregulation of CX3CL1 and causes active recruitment of CX3CR1 + Ly6C lo monocytes to tumors. Ly6C lo monocyte infiltration during anti-VEGFR2 treatment recruits neutrophils. Based on these results, we hypothesized that DC101 treatment facilitates early infiltration of Ly6C lo monocytes (day 5), which subsequently recruit neutrophils to these tumors (day 12) (Figure 1 ). To test this hypothesis, we selectively inhibited the infiltration of each myeloid cell subset by taking advantage of the unique expression of specific chemokine receptors on their surface, which are critical for their migration (i.e., CX3CR1 on Ly6C lo monocytes, CCR2 on Ly6C hi monocytes) (32, 59) (Supplemental Figure 2B ). There was nearly 80% depletion of Ly6C lo of Ly6C lo monocytes compared with the control (Figure 1 , D-G), had a significantly higher level of CXCL5, a chemokine known to attract CXCR2 + cells (Supplemental Figure 2D ). Ly6C lo monocytes secreted high levels of CXCL5 compared with Ly6C hi monocytes (Supplemental Figure 2 , B and C). Since neutrophils expressed CXCR2 on their surface (Supplemental Figure 2B) , we hypothesized that CXCL5 from Ly6C lo monocytes is a main chemoattractant for neutrophil recruitment. To verify this, we used anti-CX-CR2 and anti-CXCL5 neutralizing antibodies and measured impaired neutrophil migration toward Ly6C lo monocytes ( Figure  4H ). Other chemokines known to bind to CXCR2 (e.g., CXCL1 and CXCL2) did not seem to be crucial for attracting neutrophils in our models ( Figure 4H ). These results support our hypothesis that Ly6C lo monocytes secrete CXCL5 to recruit neutrophils expressing CXCR2.
Blockade of CX3CR1-dependent infiltration of Ly6C lo monocytes improves efficacy of anti-VEGFR2 therapy. We next determined the in vivo function of each myeloid cell subset by utilizing the aforementioned strategies to specifically inhibit their infiltration to tumors (Figure 4) . In Cx3cr1 -/-mice, which have reduced tumor infiltration of Ly6C lo monocytes and neutrophils ( Figure  4E ), DC101 monotherapy exerted an enhanced antitumor effect compared with the same treatment in WT mice ( Figure 5A and Supplemental Figure 6A ). On the other hand, depletion of Ly6C hi monocytes in Ccr2 -/-mice did not change the treatment efficacy of DC101 compared with WT mice ( Figure 5B and Supplemental Figure 6B) . Administration of an anti-Ly6G antibody, causing a significant reduction in Ly6G + neutrophils, enhanced the antitumor effect of DC101, independent of monocyte infiltration ( Figure 5C and Supplemental Figure 6C ). Taken together, we conclude that the hindrance of either DC101-induced early infiltration of Ly6C lo monocytes or subsequent recruitment of neutrophils is sufficient to improve the antitumor efficacy of anti-VEGFR2 therapy. Figure 5D ). We confirmed that the adoptive transfer increased the numbers of Ly6C lo monocytes and neutrophils in the tumors in Cx3cr1 -/-mice (Supplemental Figure 6, D-F) . We also adoptively transferred Ly6C lo monocytes isolated from Cx3cr1 -/-mice. Since Ly6C lo monocytes from Cx3cr1 -/-mice lack CX3CR1 expression on their surface, these adoptively transferred cells did not infiltrate into tumors and tumor weights were not increased ( Figure 5D and Supplemental Figure  6D ). Also, adoptive transfer of Ly6C hi monocytes did not increase the tumor weight compared with the DC101-treated Cx3cr1 -/-mice without cell transfer ( Figure 5D ). These data suggest that CX3CR1 signaling is the key mechanism driving Ly6C lo monocyte infiltration in CRCs and that Ly6C lo monocytes influence tumor growth.
Ly6C lo monocytes drive immunosuppression during anti-VEGFR2 treatment in CRCs.
We next asked how antiangiogenic therapyinduced Ly6C lo monocyte infiltration supports tumor growth. As shown in Supplemental Figure 1C , we observed vessel regression on days 5 and 12 after DC101 treatment without any rebound of vessel density, suggesting that tumor-infiltrating Ly6C lo monocytes or neutrophils do not seem to promote tumor angiogenesis. Consistent with this, we did not observe any significant difference in levels of Bv8 expression -previously implicated in the antiangiogenesis therapy resistance process by promoting angiogenesis (23) -between DC101-treated and control tumors in our models (Supplemental Figure 1, E and F) .
We next asked whether the tumor-infiltrated Ly6C lo monocytes are able to modulate the tumor immune microenvironment. We found that expression levels of immunosuppressive cytokines (i.e., IL-10 and TGF-β1) were high in both Ly6C lo monocytes and neutrophils in vitro (Supplemental Figure 2, B and C) . In vivo, we measured higher levels of immunosuppressive cytokines in DC101-treated tumors, which are abundantly infiltrated by Ly6C lo monocytes and neutrophils, than in the control. Further, immunostimulatory cytokines (i.e., TNF-α and IL-2) were downregulated upon DC101 treatment ( Figure 6A and Supplemental Figure 2D ). Flow cytometry analyses showed that DC101-treated tumors have significantly fewer effector CD4 + and CD8 + T cells compared with control ( Figure 6 , B and C). Interestingly, lymphocytes in DC101-treated tumors expressed more PD-1, while lymphocytes in control-treated tumors showed more granzyme B expression ( Figure 6 , D and E, and Supplemental Figure 7A ). Furthermore, tumors from DC101-treated Cx3cr1 -/-mice, which showed delayed tumor growth ( Figure 5A ), had higher numbers of CD4 + and CD8 + T cells, with more granzyme B and less PD-1 expression, compared with DC101-treated WT animals ( Figure 6 , B-E, and Supplemental Figure 7A ). Importantly, the higher numbers of CD4 + and CD8 + T cells in Cx3cr1 -/-mice were ablated when we adoptively transferred WT Ly6C lo monocytes into Cx3cr1 -/-mice ( Figure 6 , B-E). These data strongly support the mechanism that Ly6C lo monocytes are directly involved in the regulation of adaptive immunity and suggest that DC101-treated tumors became skewed toward an immunosuppressive phenotype by infiltration of Ly6C lo monocytes ( Figure 6 , A-E, and Supplemental Figure 7) .
Ly6C lo monocytes and neutrophils produce IL-10 and inhibit T lymphocyte proliferation. Since Ly6C
lo monocytes and neutrophils were more abundant in tumors with an immunosuppressive microenvironment, we further evaluated their capacity to suppress the proliferation of activated T lymphocytes. An in vitro CFSE assay revealed that both Ly6C lo monocytes and neutrophils inhibited CD8 + T cell proliferation ( Figure 6F ). Ly6C lo monocytes also prevented the proliferation of CD4 + T lymphocytes ( Figure 6G ). Furthermore, motivated by the findings that Ly6C lo monocytes and neutrophils express a high amount of IL-10 (Supplemental Figure 2 , B and C), we found that treatment with an anti-IL-10 neutralizing antibody prevented Ly6C lo monocytes and neutrophils from inhibiting T cell proliferation (Figure 6 , F and G). Thus, we hypothesize that DC101-induced recruitment of Ly6C lo monocytes and neutrophils producing IL-10 inhibits effector T cell activation, leading to a shift of the tumor microenvironment toward immunosuppression and thus to an attenuated immune response against the tumor.
In vivo nanoparticle delivery of siCX3CL1 inhibits Ly6C lo monocyte infiltration and enhances efficacy of anti-VEGFR2 therapy. To determine whether CX3CL1 is an initiating molecule to DC101 tumor resistance, we developed a gene therapy method that can be potentially translated into an effective adjunct to anti-VEGF therapy in the clinic using nanoparticles (7C1) delivering siRNA to target endothelial cells in vivo (60) (Figure 7A ).
To validate whether the application of 7C1 nanoparticles was feasible for targeting endothelial cells in the tumor microenvironment, we first used nanoparticles formulated with siTIE2, which has already been proven to be efficacious in silencing Tie2 mRNA in several tissues (60) . There was a significant decrease in TIE2 expression levels after 7C1-siTIE2 treatment in CRCs (Supplemental Figure 8A ). Next, we needed to harness specific siRNA no difference between the DC101 group and 7C1-siLUC plus DC101 group (Supplemental Figure 8 , D and E). We found that treating with 7C1-Axo-siCX3CL1 significantly enhanced the antitumor effect of anti-VEGFR2 therapy, even though there was negligible effect with 7C1-Axo-siCX3CL1 alone ( Figure 7F and Supplemental Figure 8F ). We confirmed that treatment of 7C1-Axo-siCX3CL1 markedly reduced DC101-induced upregulation of CX3CL1 in endothelial cells by measuring both mRNA and protein levels ( Figure 7 , C and D). We also observed that in vivo knockdown of Cx3cl1 mRNA significantly inhibited the infiltration of Ly6C lo monocytes into DC101-treated tumors and that subsequent tumor growth was delayed compared with control with only DC101 treatment ( Figure 7 , E and F). Consistent with our experiments using Cx3cr1 -/-mice, 7C1-Axo-siCX3CL1-treated tumors also showed subsequent decrease in Ly6G + neutrophils, but did not alter Ly6C hi monocytes ( Figure 4E and Supplemental Figure 8 , G and H). These data confirm that CX3CL1 is an important chemoattractant for Ly6C lo monocytes and contributes to the process of anti-VEGF therapy resistance. sequences with superior knockdown efficacy against CX3CL1 (siCX3CL1), especially when applied in vivo. We performed in vitro screening with 12 candidate sequences, identified as lead siRNA molecules by in silico predictions of target specificity and activity ( Figure 7B ). The best duplex with sequence 5′-gcuuGcGAGAGGGuuuAAAdTsdT-3′ (sense) (where upper-case letters represent unmodified RNA [2'-OH] residues and lower-case letters represent residues with 2'-O-methyl modification) and 5′-UUuAAACCCUCUCGcAAGCdTsdT-3′ (anti-sense) was selected for largescale synthesis and subsequent nanoparticle formulation ( Figure  7B and Supplemental Figure 8B ). Importantly, when we compared the knockdown efficiency of our siCX3CL1 (hereafter referred to as Axo-siCX3CL1) and another siRNA against CX3CL1 from a recent publication (61) , there was a dramatic enhancement in silencing efficiency for Axo-siCX3CL1 (Supplemental Figure 8C) .
Next, we examined the effect of 7C1-Axo-siCX3CL1 in combination with DC101 in CRCs. Treatment with the negative control 7C1-siLUC (silencing luciferase mRNA) did not change tumor growth or immune cell infiltration, and there was Furthermore, we find that immunosuppression, rather than angiogenesis, in the tumor microenvironment is the key mechanism conferring resistance to anti-VEGF therapy exerted by Ly6C Some reports show that low doses of anti-VEGF therapy can induce vascular normalization and improve antitumor immunity (63, 64) . It is also known that high dose or prolonged treatment of anti-VEGF therapy promotes hypoxia and immunosuppression in the tumor microenvironment in both clinical and preclinical studies (1, 6, 24, (65) (66) (67) (68) . The latter case explains one mechanism of anti-VEGF therapy resistance in patients, which is consistent with our observations in CRC models. Indeed, the therapeutic dose of bevacizumab currently used in the clinic is often considered as a high dose (69) , which is comparable to the dose we used in our study (maximum effective dose). These findings imply that immune resistance may hinder responsiveness to anti-VEGF/ VEGFR therapy. Here, we claim that high-dose anti-VEGFR2 therapy induces immunosuppression and that this occurs via an endothelial CX3CL1/Ly6C lo CX3CR1 + monocyte mechanism. In this study, we clearly distinguished 3 different innate immune cell subpopulations based on their immunophenotype (i.e., Ly6C and Ly6G) ( Figure 1C ). Although Ly6C lo monocytes have been described and characterized in previous publications, studies on their roles in vivo have been mostly in noncancer settings (32, 48, 49 
Discussion
Here we report, for what we believe is the first time, the immunosuppressive functions of Ly6C lo monocytes and identify them as an important driver of resistance during anti-VEGFR2 treatment in CRCs. To date, studies have divided Gr1
+ myeloid-derived suppressor cells (MDSCs) into 2 different subpopulations, monocytic and granulocytic (also known as polymorphonuclear) MDSCs (25-27, 42, 62) . However, Gr1 is not a single surface marker, but rather a complex of proteins Ly6C and Ly6G. Due to the complexity of Gr1, previous studies that utilized Gr1 staining were not able to provide a clear separation of the subpopulations (62) . Recent reports that adopted Ly6C and Ly6G for subpopulation separation focused only on Gr1 hi myeloid cells, which include Gr1 + (Ly6C hi ) monocytes and granulocytes (39) . Moreover, the definition of the myeloid cell subpopulations using surface markers has been ambiguous among research groups (35-38, 42, 43) . Unlike Gr1 + monocytes and granulocytic cells (6, 23, 24) , Ly6C lo monocytes represent a distinct cell population that has never been studied for its role in conferring resistance to anti-VEGF therapy.
As described above, there have been reports on the presence of several myeloid cells (i.e., Gr1 + , Ly6C
hi , or TIE2 + monocytes and granulocytic cells) and their respective roles in resistance to antiangiogenic cancer therapy. However, our data show that Ly6C lo monocytes along with their immunosuppressive functions form a distinct population of myeloid cells, which are immunophenotypically different from the Gr1 + or TIE2 + monocytes and granulocytic cells described previously. We identified Ly6C lo monocyte infiltration after anti-VEGFR2 therapy, and these cells were not observed in previous reports on anti-VEGF cancer therapy. Our study is the first report, to our knowledge, that investigates the ability of Ly6C lo monocytes to confer resistance to anti-VEGF cancer therapy. (Figure 7 ). These data indicate endothelial cellderived CX3CL1 plays a key functional role in the recruitment of Ly6C lo monocytes in CRCs during anti-VEGFR2 treatment. It could be argued that the recruitment of Ly6C lo monocytes might be explained by the antibody opsonization of the endothelial cells that express VEGFR2. However, we think this is not the case, as the increase in tumor infiltration of Ly6C lo monocytes was mimicked by the treatment of an antibody blocking VEGF (data not shown).
Tumors often escape antitumor immune responses through critical immune checkpoint molecules. The recent approval of drugs targeting PD-1 or CTLA-4 shows the potential for inhibiting these pathways. However, this strategy is effective only in some tumor types and in only a portion of patients. Recently, 2 studies revealed that inhibition of granulocyte recruitment into tumors improves the efficacy of the immune checkpoint blockade (35, 41) . Our data describing the immunosuppressive functions of Ly6C lo monocytes identify another path for the development of therapeutic strategies that can create synergy with the FDA-approved immune checkpoint inhibitors.
In addition, our cecum-imaging window, developed in this study, enabled quantification of dynamic mobilization of Ly6C lo monocytes with various types of behaviors over time, unveiling their CX3CR1-dependent infiltration into the tumor from the blood. The cecum window allowed longitudinal imaging for over 4 weeks, unparalleled by other imaging windows for the gut, that are applicable only for acute or short-term monitoring. The cecum window can be more broadly applied for investigations of both malignant and nonmalignant chronic diseases of the gut, such as inflammatory bowel disease and disorders related to the gut microbiota.
In summary, we found that Ly6C lo monocytes are important drivers of resistance to antiangiogenic therapy in CRCs through their immunosuppressive functions. Moreover, the increase in CX3CL1 after antiangiogenic therapy in mouse models mirrored the findings in human tumor specimens. This supports our model that CX3CL1 upregulation results in the recruitment of Ly6C lo monocytes, which attract neutrophils to the tumor via CXCL5 and inhibit effector T cell formation (Figure 8 ). The multistep process provides multiple points of intervention to prevent immune suppression and improve the effectiveness of anti-VEGF therapy by modulating the immune microenvironment. Figure 7A ), similar to other tumor models available in our laboratory.
Methods
In our CRC models, the expression levels of immunosuppressive cytokines (i.e., IL-10 and TGF-β1) were high in both Ly6C lo monocytes and neutrophils. DC101-treated tumors, abundantly infiltrated by Ly6C lo monocytes and neutrophils, were composed of significantly (P < 0.05) fewer effector CD4 + and CD8 + T cells, and those T cells that were present expressed more PD-1 and less granzyme B. This phenotype was ablated in Cx3cr1 -/-mice. An in vitro CFSE assay revealed that Ly6C lo monocytes inhibited CD4 + and CD8 + T cell proliferation, a phenotype reversed by using an anti-IL-10 neutralizing antibody (Figure 6, F and G) . Thus, DC101-induced recruitment of IL-10-producing Ly6C lo monocytes and neutrophils shifted the tumor microenvironment toward immunosuppression, leading to less infiltration of cytotoxic effector T lymphocytes. Recently, our group showed that modulation of innate immune cells (i.e., tumor-associated macrophages[TAMs]) subsequently regulates the activity of cytotoxic T cells in breast cancer models and that depletion of the cytotoxic T cells using anti-CD8 neutralizing antibody abrogated the effect of TAM modulation (63) . Therefore, if we deplete CD8 + T cells in our colon cancer model after blocking Ly6C lo monocyte infiltration, we would expect abrogated antitumor immunity even with decreased numbers of Ly6C lo monocytes in tumors. By genetically or pharmacologically depleting one specific subset of myeloid cells at a time, we found that Ly6C lo monocyte infiltration promoted subsequent neutrophil recruitment during anti-VEGFR2 treatment (Figure 4) . We also confirmed that the adoptive transfer of Ly6C lo monocytes alone increased the numbers of both Ly6C lo monocytes and neutrophils in tumors of Cx3cr1 -/-mice. Furthermore, these early infiltrating Ly6C lo monocytes overexpressed the chemokine CXCL5, which attracted CXCR2 + neutrophils. Other chemokines known to bind to CXCR2 (i.e., CXCL1 and CXCL2) did not seem to be important in attracting neutrophils in our models ( Figure 4H , Figure 6A , and Supplemental Figure 2D ), even though CXCL1 was previously proposed as a neutrophil attractant secreted from Ly6C lo monocytes in nontumor models (49) .
Based on our findings, we sought to develop a therapeutic strategy with the potential for clinical translation. We hypothesized that therapeutic targeting of CX3CL1 would selectively and potently block the infiltration of Ly6C lo monocytes and improve the efficacy of anti-VEGF/VEGFR2 cancer therapy. To specifically and effectively silence CX3CL1, we utilized a gene-therapy approach, taking advantage of the recent advances in siRNA design and chemistry that allow the identification of specific and highly potent sequences with minimal immune stimulation and maximal siRNA stability. We further benefited from the utilization of nanoparticle formulations capable of efficacious siRNA delivery to tumor endothelial cells with clinically suitable delivery materials (7C1).
Tumor growth was significantly (P < 0.05) delayed in combined 7C1-Axo-siCX3CL1 and DC101-treated mice compared with the DC101 single-treatment group. Based on the promising
